In a recent study at The Translational Research Institute, researchers found a new cancer vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
The new vaccine is comprised of human antibodies fused with tumor-specific protein.
The researchers are testing its capacity to target human cells while activating the memory of the tumor cells.
They hope this vaccine could be used to treat blood cancers, such as myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma, and pediatric leukemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma.
The study is published in Clinical and Translational Immunology. One author is Associate Professor Kristen Radford.
The team says the vaccine offers several key advantages over existing cancer vaccines, which have already shown promise in early clinical trials.
First, it can be produced as an ‘off the shelf’ clinical-grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines.
Secondly, this prototype vaccine targets the key tumor cells required for the initiation of tumor-specific immune responses, thereby maximizing the potential effectiveness of treatment, while minimizing potential side effects.
The researchers hope their continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future.
Copyright © 2020 Knowridge Science Report. All rights reserved.